Lexicon Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. The unaudited filing describes a development-stage biopharmaceutical company preparing for a potential U.S. launch of sotagliflozin while advancing LX9211 and other drug programs.
Financial results
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Royalties and other revenue | $0.024 million | $0.037 million |
| Research and development expense | $12.0 million | $14.9 million; down 19% |
| Selling, general and administrative expense | $19.1 million | $8.5 million; up 124% |
| Total operating expenses | $31.2 million | $23.4 million |
| Operating loss | $31.1 million | $23.4 million |
| Interest expense | $1.8 million | $0.1 million |
| Interest and other income, net | $1.0 million | $0.014 million |
| Net loss / loss per share | $31.9 million / $0.17 | $23.5 million / $0.16 |
| Net cash used in operating activities | $31.6 million | $23.4 million |
Revenue was immaterial relative to operating costs; the filing provides no meaningful operating margin. The larger SG&A expense reflected commercialization preparations, including higher personnel, professional and marketing fees, and related costs. R&D expense declined mainly with lower external development and professional services, partly offset by increased personnel and stock-based compensation.
Financial position and liquidity
- Cash and cash equivalents were $26.0 million and short-term investments were $79.9 million at March 31, 2023, totaling $105.9 million, down from $138.4 million at December 31, 2022.
- Total assets were $162.7 million; total liabilities were $74.7 million; stockholders’ equity was $88.0 million. Accumulated deficit was $1.62 billion.
- Long-term debt, net of issuance costs, was $48.8 million. The Oxford loans carry a floating rate; the rate was 12.57% at March 31, 2023. Debt is secured by a first lien on company and subsidiary assets. Lexicon reported compliance with debt covenants at quarter-end.
- Operating cash outflow was $31.6 million. Investing activities provided $12.1 million, primarily from net maturities of investments; financing activities used $0.8 million, mainly for shares withheld to satisfy restricted-stock-unit tax obligations.
Business, outlook and material developments
- Sotagliflozin’s heart-failure NDA was under FDA review, with a PDUFA target action date of May 27, 2023. Lexicon was preparing for a U.S. commercial launch if approved. The separate type 1 diabetes NDA had received a complete response letter; an FDA hearing process requested by Lexicon was ongoing.
- Lexicon reported positive Phase 2 results for LX9211 in diabetic peripheral neuropathic pain and top-line results showing evidence of effect in post-herpetic neuralgia. It disclosed that it lacked sufficient capital to support a full Phase 3 LX9211 program without a strategic collaboration or other arrangement.
- Management said current unrestricted cash and investments, together with expected collaboration cash and other sources, should fund currently planned operations for at least 12 months from the filing date. It also warned that additional financing may be needed thereafter and may not be available on acceptable terms; insufficient financing could require delays or reductions in clinical trials or R&D programs.
- On May 1, 2023, after quarter-end, Lexicon amended its Oxford facility: the available third tranche increased from $50 million to $75 million and the fourth tranche decreased from $50 million to $25 million. The third tranche was subject to timing and regulatory conditions, including availability within 60 days of U.S. approval of sotagliflozin for heart failure. The facility’s total stated capacity remained up to $150 million; $50 million had been funded as of the filing.
- Other disclosed obligations include $4.5 million in potential European regulatory-approval royalty payments in three annual installments and a $5 million LX9211 milestone upon first patient dosing in a Phase 3 trial. The company said ordinary-course legal proceedings were not expected to have a material adverse effect.
Key facts for investors to verify
- FDA outcome and timing for the heart-failure NDA, and the commercial launch, sales, reimbursement and manufacturing assumptions if approved.
- Cash runway against quarterly operating burn, and whether additional financing or collaboration proceeds will be required.
- Availability, conditions, interest cost and covenant implications of the Oxford loan tranches, including the May 1 amendment.
- Funding and partnering plans for LX9211 Phase 3 development and the status of the type 1 diabetes NDA hearing process.
- Drivers and sustainability of higher SG&A costs, alongside the company’s continued losses and limited revenue base.